Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

NCT03549338 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to administrative reasons

Conditions

Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Carcinoma

Interventions

DRUG: Sym004
DRUG: Futuximab
DRUG: Modotuximab

Sponsor

Symphogen A/S